Validation of the Turkish Brief Inventory of Treatment Expectations in Chronic Pain
- Sponsor
- Hacettepe University
- Study ID
- NCT07673874
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Chronic Pain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Survey Assessment Battery — OTHERParticipants will complete a comprehensive survey battery including: Sociodemographic and Clinical Information Form Turkish Brief Inventory of Treatment Expectations in Chronic Pain (BITEC-TR) Treatment Expectations in Chronic Pain Scale Pain Catastrophizing Scale (PCS) Numerical Pain Rating Scale (NPRS) Hospital Anxiety and Depression Scale (HADS)
Study Details
The purpose of this study is to conduct the Turkish cross-cultural adaptation, validity, and reliability study of the "Brief Inventory of Treatment Expectations in Chronic Pain" (BITEC) scale. Chronic pain is a complex, multidimensional experience that affects a significant portion of the adult population. Treatment expectations play a critical role in predicting clinical outcomes and directly influencing placebo/nocebo responses. While several tools exist to evaluate expectations, there is a lack of a concise, clinician-friendly, and Item Response Theory (IRT)-based instrument adapted for Turkish chronic pain populations. The BITEC is a 9-item scale that evaluates biological, psychological, and social/interactional expectation domains. This methodological and cross-sectional study will be conducted with adult patients diagnosed with chronic pain for at least three months at Bingöl State Hospital. The study will be carried out in four consecutive stages: cross-cultural adaptation (forward and backward translation), comprehensibility pre-testing (with 30-40 volunteers), main data collection (with at least 200 participants), and statistical analyses. Data will be collected through printed forms and an online survey platform (Kobotoolbox), involving no clinical interventions. Participants will complete a sociodemographic information form, the Turkish version of the BITEC (BITEC-TR), the Treatment Expectations in Chronic Pain Scale (TEC-TR), the Pain Catastrophizing Scale (PCS), the Numerical Pain Rating Scale (NPRS), and the Hospital Anxiety and Depression Scale (HADS). Additionally, a subgroup of approximately 60 participants will recomplete the BITEC-TR 7-10 days after the initial session to evaluate test-retest reliability. Psychometric evaluation will include construct validity through exploratory and confirmatory factor analyses, and internal consistency and stability measurements.
Key Dates
- First listed
- Jun 29, 2026
- Start date
- Sep 1, 2026
- Status verified
- Jun 2026
- Primary completion
- May 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 250 participants (estimated)
Arms
- Arm: Patients with Chronic PainAdult patients aged 18-70 who have been experiencing non-cancer chronic pain for at least three months, are literate, and are currently receiving medical treatment. Data will be collected through printed forms or the online survey platform Kobotoolbox.
Primary Outcome Measure
Turkish Brief Inventory of Treatment Expectations in Chronic Pain (BITEC-TR) Score [ Time Frame: Baseline (Day 1) and 7-10 days later for the test-retest subgroup. ]
Central Contacts
- Aybüke Fanuscu+9004262160012-5548
Related Studies
- Patient Retrospective Outcomes (PRO)Recruiting · Boston Scientific Corporation · Lake Havasu City, Arizona
- QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory TestingRecruiting · Anna Evans Phillips · Baltimore, Maryland
- Long-Term Real-World Outcomes Study on Patients Implanted With a NeurostimulatorRecruiting · Abbott Medical Devices · Phoenix, Arizona
- PAIN: A Project Assessing the Impact of a Novel Cannabinoid ProductPHASE2 · Recruiting · Staci Gruber, Ph.D. · Belmont, Massachusetts